New cream promises smoother recovery after eyelid surgery

NCT ID NCT07234292

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a new preservative-free eyelid cream helps people feel more comfortable after eyelid surgery. About 30 adults who are planning eyelid surgery will use the cream twice a day for 3 months. Researchers will measure how satisfied patients are with their eyelid comfort using a simple 0-to-10 scale.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

A total of 30 patients undergoing blepharoplasty or ptosis surgery

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years old * Patients planning a blepharoplasty or a ptosis surgery in at least one eye. * Patient affiliated to a health social security system * Female of childbearing potential should use a medically accepted contraceptive regimen since at least 12 weeks before the beginning of the study, during all the study and at least 1 month after the study end. Exclusion Criteria: In terms of population: * Pregnant or nursing woman or planning a pregnancy during the study. * Patient who had been deprived of their freedom by administrative or legal decision * Minor patient. * Major patient who is under guardianship or who is not able to express his non opposition. * Patient suspected to be non-compliant according to the investigator's judgment. * Patient enrolled in another clinical trial or which exclusion period is not over. In terms of associated pathology * Patient with a history or active systemic condition or receiving a medication which, in the investigator's judgment, put the patient at undue risk. * Patient suffering from a severe or progressive disease. * Patient with known or suspected hypersensitivity to one of the components of the product. Related to previous or ongoing treatment * Patient undergoing a topical treatment on the test area or a systemic treatment. * Patient under a long-term corticosteroid, NSAID or HIV therapy at the investigator appreciation. * Patient under immunosuppressive therapy * Patient under bisphosphonate therapy * Patient having Type 1 diabetes * Patient having atopic or eczema skin In terms of lifestyle * Intensive exposure to sunlight or UV-rays foreseen during the study. * Patient planning to change her/his life habits during the study. * Patient with an excessive consumption of alcohol and/or tobacco defined as: * an excessive consumption of alcohol: Drinking more than * 4 units a day for adult men and more than 2 units a day for adult women, * an excessive consumption of tobacco: ≥15-20 Cigarettes Per Day (CPD).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Eyelid; wound are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Pierre-Vincent Jacomet Private Practice

    RECRUITING

    Paris, France